Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Grazoprevir/elbasvir highly effective in treatment-experienced a nd HIV-coinfected hepatitis C patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in

Published
15 hours ago
By
Keith Alcorn
Grazoprevir / elbasvir highly effective in previously untreated hepatitis C

A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with gentoypes 1, 4 or 6 hepatitis C infection, according to

Published
24 April 2015
By
Keith Alcorn
Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease

An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85-88% for genotype 1 or 4

Published
24 April 2015
By
Liz Highleyman
Merck HCV combination achieves 90% cure in advanced cirrhosis

A 12-week course of treatment with two direct-acting antivirals in development by Merck cured hepatitis C infection in 90% of people with very advanced cirrhosis and at

Published
23 April 2015
By
Keith Alcorn
Merck HCV combination effective after failure of first generation of direct-acting antivirals

A 12-week course of treatment with two direct-acting antivirals in development by Merck  plus ribavirin cured 95% of people with hepatitis C who had experienced failure of

Published
23 April 2015
By
Keith Alcorn
EASL Recommendations on Treatment of Hepatitis C 2015

These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections.

Published
23 April 2015
From
EASL
Gilead uses Georgia as free-drug testbed for hepatitis C elimination

Gilead Sciences is seeking to convince governments and multilateral agencies worldwide that hepatitis C can be eliminated with a demonstration project in Georgia offering free drugs to all those who need them.

Published
23 April 2015
From
Reuters
Report: Hepatitis C in Eastern Europe and Central Asia: Epidemic and Response

The purpose of this report is to provide an overview of some of the key aspects of the hepatitis C (HCV) epidemic and response in Eastern Europe and Central Asia (EECA). It is also intended to outline tools and opportunities for civil society (CS) and community-based groups and individuals working on expanding access to HCV treatment in the region.

Published
23 April 2015
From
EATG
HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy

Direct-acting antiviral regimens containing sofosbuvir (Sovaldi) and the drugs in Viekirax/Exviera were highly effective regardless of how soon hepatitis C viral load became undetectable after starting treatment, according to

Published
23 April 2015
By
Liz Highleyman
Union of South American Nations (UNASUR) proposes centralised purchase of hepatitis C treatments Olysio and Sovaldi for member states

Regional agency UNASUR is aiming to secure price discounts on Sovaldi (sofosbuvir; Gilead Sciences, US) and Olysio (simeprevir; Janssen-Cilag, US), generating savings and reducing the risk of compulsory licences or price cuts.

Published
21 April 2015
From
IHS
← First12345...56Next →

Filter by country